| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$42 |
1H FY26 Results Announcement
|
26 Feb 2026 8:34AM |
$0.260 |
$0.220 |
fallen by
15.38%
|
|
GTN - Price-sensitive ASX Announcement
Full Release
Key Points
- GTN Limited announced 1H FY26 results, reporting financial challenges.
- Implemented cost base reset and market repositioning strategies.
- Returned $43.9 million to shareholders, maintaining strong liquidity.
- Revenue of $82.5 million and adjusted EBITDA of $5.8 million, indicating declines.
- A $41.5 million non-cash impairment charge recognized.
- Declared an interim dividend of $0.01 per share, unfranked.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QuickFee Limited (QFE) ORDINARY FULLY PAID |
Financials |
$29 |
Notice under section 708A(5) of the Corporations Act 2001
|
26 Feb 2026 8:34AM |
$0.079 |
$0.076 |
fallen by
3.80%
|
|
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$56 |
Half Year Report and Appendix 4D
|
26 Feb 2026 8:34AM |
$0.032 |
$0.034 |
risen by
6.25%
|
|
SNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Syntara Limited reported a significant decline in revenues and an increase in losses for the half-year ended 31 December 2025.
- Revenues from ordinary activities decreased by 36.9% to $3,472,000.
- The loss from continuing operations after tax increased by 117.6% to $6,051,000.
- No dividends were paid, recommended, or declared during the period.
- The company's lead drug candidate, amsulostat (SNT-5505), progressed in clinical development for conditions like myelofibrosis and myelodysplastic syndromes.
- Syntara gained Orphan Drug Designation from the European Medicines Agency, ensuring market exclusivity for amsulostat in Europe.
- The company started a Phase 2 study in Australia for amsulostat in myelodysplastic syndromes, supported by funding from the Australian Government.
- Total assets decreased to $14,055,000 from $21,443,000 as of 30 June 2025.
- Net cash outflow from operating activities was $4,496,000 for the half-year.
- There was no audit qualification or review dispute for the financial statements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$42 |
XRG Investor Presentation HY26
|
26 Feb 2026 8:33AM |
$0.051 |
$0.056 |
risen by
9.80%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Record half-year performance driven by Operator XR product.
- Total revenue for H1 FY26 increased to $10.4 million, up 41% year-over-year.
- Net profit after tax of $0.7 million, an improvement of $1.7 million from previous period.
- EBITDA increased to $2.6 million, up 190% from year-over-year.
- Annual recurring revenue from Operator XR grew to $6.2 million.
- Sales pipeline increased to $63 million, up 107% year-to-date.
- Expansion into U.S. and other high-growth global markets.
- Launch of Counter-Drone capability to enhance product offerings.
- Strategic focus on Operator XR as core growth engine.
- Exit from legacy VR entertainment operations almost complete.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$42 |
Dividend/Distribution - GTN
|
26 Feb 2026 8:33AM |
$0.260 |
$0.220 |
fallen by
15.38%
|
|
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$26 |
Investor call presentation
|
26 Feb 2026 8:32AM |
$0.060 |
$0.063 |
risen by
5%
|
|
| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$42 |
Appendix 4D and Half Year Financial Report
|
26 Feb 2026 8:32AM |
$0.051 |
$0.056 |
risen by
9.80%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 41% to $10,437,227.
- Profit after tax was $733,205.
- No dividends declared for the half-year.
- Net tangible assets per security increased to $0.006.
- Continued investment in product capability and content development.
- Shift towards a software-led, recurring revenue model.
- Strong operating cash flow and successful debt repayment.
- Directors confident in the Group's financial stability and future operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$42 |
Appendix 4D and Half Year Financial Statements
|
26 Feb 2026 8:32AM |
$0.260 |
$0.220 |
fallen by
15.38%
|
|
GTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of $40.9 million reported for the half-year ending 31 December 2025.
- Revenue declined by 14.7% to $82.5 million.
- Impairment charge of $41.5 million affected financial results.
- Brazil was the only market with revenue growth.
- A $43.9 million capital return was executed.
- Interim dividend declared at $0.01 per share, unfranked.
- Auditor confirmed compliance with legislative and professional standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$122 |
Appendix 4D
|
26 Feb 2026 8:31AM |
$0.265 |
$0.195 |
fallen by
26.42%
|
|
ANG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations down 3.0% to AUD 170.3 million.
- EBITDA from continuing operations down 63.0% to AUD 8.0 million.
- Profit from continuing operations after income tax down 85.4% to AUD 2.0 million.
- Profit after tax attributable to members down 86.1% to AUD 1.8 million.
- Interim dividend of 0.3 cents per share declared, fully franked.
- Net tangible assets per ordinary share decreased to 18.53 cents.
- No acquisitions, associates, or joint ventures were reported.
- Financial report reviewed with an unqualified report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$399 |
CVW Investor Presentation - HY26
|
26 Feb 2026 8:31AM |
$0.625 |
$0.635 |
risen by
1.60%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported underlying NPAT from continuing operations is $22.1 million.
- In-force premiums increased to $436.0 million, up 13%.
- Clearview's balance sheet reflects $806.5 million in total assets and $348.4 million in net assets.
- A $120 million Tier 2 note was issued in March 2025, with $75 million redeemed in November 2025.
- The ClearChoice product now constitutes 31% of the in-force portfolio.
- The presentation provides an economic impact analysis on AASB 17 liability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImpediMed Limited (IPD) ORDINARY FULLY PAID |
Health Care |
$33 |
FY26 Half Year Financial Results
|
26 Feb 2026 8:30AM |
$0.019 |
$0.016 |
fallen by
15.79%
|
|
IPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for H1 FY26 was $7.5 million, up 25% compared to the prior period.
- Gross margin remained strong at 87%.
- Significant improvement in U.S. reimbursement coverage to 93%.
- Annual Recurring Revenue increased to $14.4 million, up 15%.
- SOZO® Core Business Total Contracted Value rose to $8.7 million, up 9%.
- Entry into Heart Health market with initial sales in Texas.
- Launch in weight management and body composition market targeting a A$650 million market.
- Expanding U.S. pipeline with 700 potential units, representing over US$35 million in potential contract value.
- Focus on capital management and operational efficiency for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImpediMed Limited (IPD) ORDINARY FULLY PAID |
Health Care |
$33 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 8:30AM |
$0.019 |
$0.016 |
fallen by
15.79%
|
|
IPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 25% to $7,516,000.
- Net loss attributable to members increased by 25% to $12,349,000.
- No dividends were declared or paid during this period.
- The SOZO product line remains a primary focus for revenue.
- The company continues to rely on raising additional capital and maintaining borrowing facilities.
- Costs in salaries, benefits, and operational areas are high contributing to the loss.
- The financial statements comply with AASB 134 and Corporations Act 2001.
- The report was approved for release by the Board of ImpediMed Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$399 |
CVW Market Release HY26 Results
|
26 Feb 2026 8:30AM |
$0.625 |
$0.635 |
risen by
1.60%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Life Insurance Underlying NPAT up 59% to $24.1m
- Group Underlying NPAT up 77% to $22.1m
- Group Underlying EPS increased to 3.5 cents per share
- Gross premium income rose by 13% to $215.6m
- New business growth increased by 29%
- Simplification and transformation strategy completed
- ClearView operating on a single cloud-based insurance platform
- ClearView's net assets are $348.4m
- A scheme of arrangement with Zurich Financial Services announced
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,687 |
Net Tangible Asset Backing
|
26 Feb 2026 8:30AM |
$4.400 |
$4.240 |
fallen by
3.64%
|
|
| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$13,740 |
Qantas Group HY26 Results Investor Presentations
|
26 Feb 2026 8:29AM |
$10.650 |
$9.080 |
fallen by
14.74%
|
|
QAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying profit before tax of $1,456 million.
- Statutory profit after tax of $925 million.
- Operating cash flow of $1.8 billion.
- Shareholder distributions up to $450 million.
- Introduction of A321XLR and A220 models.
- 19% revenue increase in Qantas Loyalty.
- Strategic focus on sustainability and operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$399 |
CVW Half Year Consolidated Financial Report
|
26 Feb 2026 8:29AM |
$0.625 |
$0.635 |
risen by
1.60%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,196 |
2025 Corporate Governance Statement and Appendix 4G
|
26 Feb 2026 8:29AM |
$4.840 |
$4.270 |
fallen by
11.78%
|
|
| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$13,740 |
Qantas Group HY26 Results ASX and Media Release
|
26 Feb 2026 8:29AM |
$10.650 |
$9.080 |
fallen by
14.74%
|
|
QAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong financial results for 1H26 with a $1.46 billion Underlying Profit Before Tax.
- Continued fleet expansion and introduction of new aircraft, including A321XLR and A350s for Project Sunrise flights.
- Jetstar's profitability driven by new aircraft and network expansions.
- Qantas Loyalty achieved a 12% increase in Underlying EBIT, driven by member engagement and partnerships.
- Approval of a $300 million fully franked interim base dividend and a share buyback of up to $150 million.
- Outlook includes strong travel demand and further fleet investments.
- Challenges addressed through transformation to manage rising costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,196 |
2025 Full Year Investor Reference Pack
|
26 Feb 2026 8:28AM |
$4.840 |
$4.270 |
fallen by
11.78%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria operates toll roads in France, Germany, and the United States.
- The Investor Reference Pack is supplementary to the full Financial Report.
- APRR, ADELAC, and Chicago Skyway are key assets.
- Financial metrics include cash flow statements and debt details.
- Concession expiries for assets range from 2035 to 2068.
- The document should be read with the full Financial Report for comprehensive insights.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$399 |
Appendix 4D
|
26 Feb 2026 8:28AM |
$0.625 |
$0.635 |
risen by
1.60%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- ClearView Wealth Limited's Appendix 4D for the half year ended 31 December 2025.
- Revenue from ordinary activities increased by 14% to $202.021 million compared to the previous corresponding period.
- Profit from ordinary activities after tax attributable to members from continuing operations decreased by 55% to $8.537 million.
- The net profit for the period attributable to members decreased by 46% to $8.537 million.
- There were no entities over which control was gained or lost during the period.
- No associates and joint ventures were reported as at 31 December 2025.
- An on-market buy-back program was announced, and $10.3 million worth of shares were purchased over the period.
- No dividend was declared for HY26 and FY25.
- Net tangible assets per security as of 31 December 2025 were 48.2 cents.
- The report is filed under ASX Listing Rule 4.2A.3.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$13,740 |
Notification of buy-back - QAN
|
26 Feb 2026 8:28AM |
$10.650 |
$9.080 |
fallen by
14.74%
|
|
| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$13,740 |
Dividend/Distribution - QAN
|
26 Feb 2026 8:28AM |
$10.650 |
$9.080 |
fallen by
14.74%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,196 |
2025 Full Year Results Presentation
|
26 Feb 2026 8:27AM |
$4.840 |
$4.270 |
fallen by
11.78%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax: $181.8 million, a 39% decrease from 2024.
- Toll revenue increased by 10% to $158.9 million.
- Cash flow: $549 million distributions from businesses.
- Stable distributions per security at 40 cents for the full year.
- Total assets of $7,655.8 million and net assets of $5,802.3 million.
- Significant investments in APRR and Chicago Skyway.
- Refinancing of APRR RCF with a maturity date extended to February 2031.
- Strong credit ratings: Fitch 'A Stable' and S&P 'A- Stable'.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$13,740 |
Half Yearly Report and Accounts
|
26 Feb 2026 8:27AM |
$10.650 |
$9.080 |
fallen by
14.74%
|
|
QAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory profit before income tax was $1,307 million for the half-year ended 31 December 2025.
- Net passenger revenue increased by 6% to $11,063 million.
- Operating expenses excluding fuel rose by 7% to $7,615 million.
- Net cash inflow from operating activities was $1,752 million.
- Qantas Group's net assets increased to $1,349 million from $783 million in 2024.
- Closure of Jetstar Asia and fleet redistributions were significant strategic actions.
- Group capacity increased by 4% in terms of Available Seat Kilometres.
- Revenue Passenger Kilometres rose by 3%, while the Seat Factor slightly decreased to 84.7%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$507 |
Notification of buy-back - OML
|
26 Feb 2026 8:27AM |
$0.950 |
$0.950 |
fallen by
0%
|
|
Call 1300 880 160
Start a chat
Schedule a call
